Dr. McNamee, MD of CSL, has presented the pro-competitive arguments of CSL’s case with the FTC staff, including efficiencies and benefits to consumers resulting out of the acquisition, put forward the potential remedies that may enable approval and discussed the consideration of the case.
Following the review of CSL’s case and remedy proposals, FTC staff has recommended that the Commissioners initiate legal action in the US District Court to stop the transaction. A vote and decision by the Commissioners is pending, expected to be announced by 28 May 2009.